GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » FCF Margin %
中文

Telo Genomics (Telo Genomics) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Telo Genomics's Free Cash Flow for the three months ended in Dec. 2023 was $-0.51 Mil. Telo Genomics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Telo Genomics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Telo Genomics's current FCF Yield % is -24.23%.

The historical rank and industry rank for Telo Genomics's FCF Margin % or its related term are showing as below:


TDSGF's FCF Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -10.51
* Ranked among companies with meaningful FCF Margin % only.


Telo Genomics FCF Margin % Historical Data

The historical data trend for Telo Genomics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, Telo Genomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics FCF Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Telo Genomics's FCF Margin % falls into.



Telo Genomics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Telo Genomics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-2.032/0
= %

Telo Genomics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.509/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Telo Genomics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.